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Abstract
Background: Artemisinin-based combination treatments (ACTs) are the first-line treatments of uncomplicated
Plasmodium falciparum malaria in many endemic areas but there are few evaluation of their efficacy in anaemic
malarious children.
Methods: Therapeutic efficacy of 3-day regimens of artesunate-amodiaquine and artemether-lumefantrine was evaluated
in 437 anaemic and 909 non-anaemic malarious children following treatment during a seven-year period (2008–2014).
Patterns of temporal changes in haematocrit were classified based on haematocrit values <30% and ≥30%. Kinetics of the
disposition of the deficit in haematocrit from 30% following treatment were evaluated using a non-compartment model.
Results: PCR-corrected parasitological efficacy 28 days after start of treatment was significantly higher in artesunate-
amodiaquine- compared to artemether-lumefantrine-treated children [97% (95%CI: 92.8–100) versus 96.4%
(95%CI: 91.3–99.4), P = 0.02], but it was similar in non-anaemic and anaemic children. Fall in haematocrit/1 000 asexual
parasites cleared from peripheral blood was significantly greater at lower compared to higher parasitaemias (P < 0.0001),
and in non-anaemic compared to anaemic children (P = 0.007). In anaemic children at presentation, mean
anaemia recovery time (AnRT) was 15.4 days (95%CI: 13.3–17.4) and it did not change over the years. Declines in
haematocrit deficits from 30% were monoexponential with mean estimated half-time of 1.4 days (95%CI: 1.2–1.6).
Anaemia half-time (t½anaemia) correlated positively with AnRT in the same patients (r = 0.69, P < 0.0001). Bland-Altman
analysis of 10 multiples of t½anaemia and AnRT showed narrow limit of agreement with insignificant bias (P = 0.07)
suggesting both can be used interchangeably in the same patients.
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Conclusions: Artesunate-amodiaquine and artemether-lumefantrine remain efficacious treatments of uncomplicated
P. falciparum infections in non-anaemic and anaemic Nigerian children in the last 7 years of adoption as first-line
treatments. These ACTs may also conserve haematocrit at high parasitaemias and in anaemic children.
Trials registration: Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201510001189370, 3
July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015.
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Background
Recommended as the first-line treatments of uncompli-
cated Plasmodium falciparum malaria globally [1],
artemisinin-based combination treatments (ACTs) have
remained largely efficacious globally except in the
Greater Mekong subregion where artemisinin resistance
in P. falciparum has recently emerged [2–7]. Not only
do these drug combinations clear asexual and immature
sexual parasitaemia rapidly and prevent progression of
committed and non-committed asexual parasites to
sexual forms, they may also prevent destruction of once-
parasitized (once-infected) red blood cells through a
splenic process called “pitting”. Pitting removes the dead
parasites from parasitized red blood cells and returns
the once-infected red blood cells into circulation [8–10].
This process prevents precipitous falls in haematocrit in
the first few days following ACTs particularly when
parasitaemias are high. In severe malaria, pitting is a
life-saving process [10].
It has been suggested that in resource-poor endemic
countries, the degree of precipitous falls in haematocrit
following ACTs can be measured by estimating the fall
in haematocrit per 1 000 red blood cells cleared from
peripheral blood in the first two days following treat-
ment [11]. The relatively little or no fall in baseline
(pre-treatment) haematocrit in the first few days following
treatment, particularly when parasitaemias are high, has
been termed “haematocrit conservation” [11].
In many endemic and non-endemic areas of the world,
anaemia is an inevitable consequence of untreated P.
falciparum infections. Anaemia may occur in 10 – 90%
of children or non-immune individuals presenting with
acute infections [12–18]. Malaria-associated anaemia
contributes significantly to morbidity or mortality in P.
falciparum malaria [19–25]. Despite the frequent occur-
rence of malaria-associated anaemia in children living in
endemic areas, the efficacy of artemisinin-based combin-
ation treatments and the adverse events following their
use have been little evaluated in anaemic children with
uncomplicated P. falciparum infections.
It has recently been reported that intravenous artesu-
nate treatment may cause delayed haemolysis in immuno-
logically naïve patients with severe malaria [10, 26–31].
However, it is unclear if artemisinin-based combination
treatments conserve haematocrit in anaemic children
following treatment of uncomplicated P. falciparum infec-
tions. It is also unclear if the conserved haematocrit is
subsequently lost resulting in a late-appearing anaemia in
children with uncomplicated infections.
In Nigeria, artemether-lumefantrine and artesunate-
amodiaquine, in that order, were adopted as first-line
treatments of uncomplicated P. falciparum malaria in
2005 [32]. Both ACTs have been evaluated, using stan-
dardised protocols, more or less continuously at one of
seven sentinel sites set up by Nigeria’s Federal Ministry
of Health in six geographical areas of Nigeria. These
sentinel sites were set up to monitor the efficacy of anti-
malarial drugs. There is no reported study, in Nigerian
children, of the efficacy of artemether-lumefantrine and
artesunate-amodiaquine in the last seven years of their
adoption as first-line treatments.
The aims of the present study during a 7-year period
of adoption are: (i) to evaluate the efficacy of artesunate-
amodiaquine and artemether-lumefantrine in uncompli-
cated P. falciparum malaria, (ii) to determine if efficacy
of artesunate-amodiaquine and artemether-lumefantrine
differs between malarious anaemic and malarious non-
anaemic children, and if ACTs conserve haematocrit in
anaemic children, (iii) to evaluate recovery from malaria-
associated anaemia, and (iv) to elucidate the temporal
changes in haematocrit following treatment with
artesunate-amodiaquine and artemether-lumefantrine
in anaemic malarious children.
Methods
Study locations
The studies were part of a programme to monitor anti-
malaria therapeutic efficacy at seven sentinel sites
located in six geographical areas of Nigeria (Fig. 1).
These sites were established by Nigeria’s Federal Ministry
of Health. These studies were conducted between
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October 2009 and November 2010 at the following
locations: Agbani, Ikot Ansa, Barkin Ladi and Damboa,
in Enugu, Cross River, Plateau and Borno States, re-
spectively (the eastern flank of the study sites), and in
Ijede, and Makarfi in Lagos, and Kaduna States, re-
spectively (the western flank). The studies were also
conducted continuously in Sabo quarters of Ibadan,
Oyo State (the reference centre), located on the western
flank from 2008 to 2014 (Fig. 1). In virtually all study
locations, malaria is endemic and transmission occurs
all year round; however, it is more intense during the
rainy season from April to October. P. falciparum is
the predominant species, accounting for over 98% of all
infections [33, 34]. Children are more affected than
adults, and apparently, asymptomatic infections occur
in older school children and adults [33]. The overall
study profile is shown in Fig. 2.
Study procedures
Standardised procedures and protocol were used at all
sentinel sites [35–40]. Briefly, patients were eligible to
participate in the study if they were: aged 6 months–
15 years, had symptoms compatible with acute uncom-
plicated malaria with P. falciparum mono-infections ≥1
000 μL−1 of blood, no history of antimalarial drug inges-
tion in the two weeks prior to enrolment, absence of
severe malaria and written informed consent given by
parents or guardians.
Enrolled patients were randomized to receive
artemether-lumefantrine or artesunate-amodiaquine (co-
formulated) for 3 days (days 0–2) as previously described
[35, 40]. The day of presentation (day of starting treat-
ment) was regarded as day 0. Thick and thin blood films
were obtained from each child as soon as they came to
the clinic and the slides were carefully labelled with the
patients’ codes and air-dried before being stained.
Follow-up with clinical and parasitological evaluation
was done daily on days 1–3 and on days 7, 14, 21, 28 at
all study sites except in Ibadan where additional follow-
up was done on days 35 and 42. Parasitaemia, asexual or
sexual, in thick films was estimated by counting asexual
and sexual parasites relative to 500 leukocytes, or 500
asexual or sexual forms whichever occurred first. From
this figure, the parasite density was calculated assuming a
leukocyte count of 6 000 μL−1 of blood [41–43]. Sexual
parasitaemia was estimated only in Ibadan, but their pres-
ence or absence was recorded at other sites. A slide was
considered asexual parasite negative if no asexual parasite
was detected after examination of 200 microscope fields.
The cure rates on days 28 and 42 were adjusted on
the basis of the polymerase chain reaction (PCR) geno-
typing results of paired samples of patients with recur-
rent parasitaemia after day 7 of starting treatment using
the World Health Organisation 2003 and 2009 proto-
cols [44, 45] as previously described [35–38]. The clin-
ical classification system consisted of the following
Fig. 1 Map of Nigeria showing study locations in seven states
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categories of response: adequate clinical and parasito-
logical response (ACPR), late parasitological failure (LPF),
late clinical failure (LCF), early treatment failure (ETF).
The primary outcomes were the 28-day uncorrected and
PCR-corrected efficacy. Asexual parasite reduction ratio
(PRR) [46] was defined as the ratio of day 0/day 2 parasit-
aemia (and for convenience, referred to as PRRD2). If there
was complete clearance of parasitaemia on day 2, parasit-
aemia was assumed to be 1 uL−1, a level below micro-
scopic detection. Asexual parasite reduction ratio on day
1 (PRRD1) was defined as the ratio of day 0/day 1 parasit-
aemia. If there was complete clearance of parasitaemia on
day 1, parasitaemia was assumed to be 1 uL−1, a level
below microscopic detection.
Haematological evaluation
Capillary blood collected before and during follow-up was
used to measure haematocrit using a microhaematocrit
tube and microcentrifuge (Hawksley, Lancing, UK).
Anaemia was defined as a haematocrit <30% and was
classified as mild, moderate or severe if haematocrit was
21-29%, 15-20% or <15%, respectively. Anaemia recovery
time (in anaemic patients) was defined as time elapsing
from drug administration to attainment of a haematocrit
value ≥30% and was evaluated in children with haemato-
crit ≤25% at presentation. In patients who had early or late
monophasic declines in haematocrit which resulted in an-
aemia, anaemia recovery time was defined as time from
appearance of, to recovery from, anaemia. Fall in
haematocrit per 1 000 asexual parasites cleared from
peripheral blood following treatment (FIH/1 000
asexual parasites cpb) was defined as numeric esti-
mation of relative difference in haematocrit at base-
line (pre-treatment) and the first 1 or 2 days after
treatment began as numerator, and the corresponding
relative difference in parasitaemia as the denominator, and
Fig. 2 Study profile. AA, artesunate-amodiaquine; AL, artemether-lumefantrine, * follow-up was for 42 days, ** follow-up was for 28 days,
*** randomization at a ratio of 2:1 for artesunate-amodiaquine and artemether-lumefantrine, # number of children that completed follow-up
period, ^ children are <5 years old.
Sowunmi et al. Infectious Diseases of Poverty  (2017) 6:36 Page 4 of 20
expressing it per 1 000 asexual parasites cleared
from peripheral blood FIH1000 asexual parasite cpb ¼

Haematocrit on day 0−Haematocrit on day 1 or 2
Parasitaemia on day 0−Parasitaemia on day 1 or 2 1000 [11].
Fig. 3 is the profile of investigations carried out dur-
ing the study.
Evaluation of temporal changes in haematocrit in anaemic
children following treatment
Haematocrit <30% and ≥30% were the reference points
in all classified patterns and was modified from a re-
cently described patterns [47]. Temporal changes in
haematocrit were classified into the following patterns.
1. Haematocrit <30% before treatment followed by an
increase to ≥30% after treatment (malaria-associated
anaemia at presentation and recovery from anaemia).
2. Haematocrit <30% followed by a rise to ≥30% by
day 7, a fall to <30% between days 7 and 14 and
then recovery (anaemia–early recovery–anaemia–
late recovery).
3. Haematocrit <30% followed by a rise to ≥30% on day 7
or 14, followed by two consecutive normal haematocrits
and decline to <30% after day 14 (anaemia–early
recovery–late-appearing anaemia pattern).
4. Haematocrit <30% before treatment began and
during the entire follow-up period (persistent, unre-
solved anaemia).
5. Multiple falls in haematocrit below 30%, a rise to
≥30% during follow-up period and then a fall below
30% (undulating pattern of anaemia).
6. Unclassifiable.
In non-anaemic patients (n = 568), evaluation of tem-
poral changes was limited to those who had falls in
haematocrit to anaemic level 3–6 weeks after com-
mencement of treatment as previously described [47].
Kinetics of the disposition of deficit in haematocrit
from 30%
The kinetics of the disposition of deficit in haematocrit
from 30%, that is, of anaemia, was as previously de-
scribed [35, 37, 47]. Briefly, in all anaemic patients with
a haematocrit value ≤25% at enrolment, or when an-
aemia occurs following treatment, haematocrit values
below 30% (the lower threshold of normal) and at
follow-up were subtracted from 30% at each time of
measurement until haematocrit rose to ≥30%, and the
resulting values plotted against time. The final haemato-
crit when anaemia resolved was therefore zero in all pa-
tients. However, the final haematocrit at the time of
resolution or recovery was assumed to be 0.01%. The
areas under the curve (AUC) of deficit in haematocrit
(from 30%) versus time were obtained, by trapezoidal rule
using the computer program Turbo Ken (designed by
Clinical Pharmacology Group, University of Southampton,
Fig. 3 Profile of investigations carried out. PRRD1, parasite reduction ratio 1 day after treatment began; PRRD2, parasite reduction ratio 2 days after
treatment began; PCT, parasite clearance time; FCT, fever clearance time; FIH, fall in haematocrit per 1 000 asexual parasites cleared from peripheral
blood; PD, pharmacodynamic measure of recovery (anaemia recovery time); PK, pharmacokinetic measure of recovery (anaemia half-time);
AA, artesunate-amodiaquine; AL, artemether-lumefantrine
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United Kingdom) as previously described [35, 37]. AUC
was also obtained manually by calculating the average
haematocrit values between two consecutive time mea-
surements and multiplying it by the time interval between
the measurements, and summing up all the values, in a
manner similar to that for the numerical estimation of
area under a drug concentration-time curve [48]. The unit
of quantification would be %.d, if haematocrit values were
used or g/L.d if haemoglobin values were used. Haemato-
crit values may be converted to haemoglobin values by
dividing by 3 [49]. Semilog plots of deficit in haemato-
crit versus time were plotted. The apparent terminal
elimination rate constant (λ) was obtained by least-
square regression analysis of the post-peak log-linear
part of the plot of deficit in haematocrit (from 30%)
versus time, and the apparent terminal half-time of
anaemia (t1/2(anaemia)) was calculated from ln 2/(λ) (that
is, λt = 0.693).
Statistical analysis
Data were analysed using version 6 of Epi-Info soft-
ware [50] and the statistical program SPSS for
Windows version 20.0 [51]. Variables considered in the
analysis were related to the densities of P. falciparum
asexual and sexual forms. Proportions were compared
by calculating χ2 using Yates’ correction, Fisher’s exact
or Mantel Haenszel tests. Normally distributed, con-
tinuous data were compared by Student’s t test and
analysis of variance (ANOVA). Data not conforming to
a normal distribution were compared by the Mann–
Whitney U tests and the Kruskal Wallis tests (or by
Wilcoxon ranked sum test). The cumulative risk of
parasite reappearance was calculated by survival ana-
lysis using Kaplan-Meier method. Correlation between
anaemia recovery time and anaemia half-time in the
same patients was assessed by Pearson’s correlation co-
efficient. Agreement between multiples of anaemia
half-time (proposed pharmacokinetic method of asses-
sing response to treatment) and anaemia recovery time
(standard pharmacodynamic method of assessing re-
sponse to treatment) in the same patients was assessed
by Bland-Altman analysis [52]. Impacts of treatments
over time were evaluated using test for trend for the
following parameters: parasitological efficacy, late
parasitological failure and gametocyte carriage, and by
comparison of mean or median at specific time inter-
vals for the following parameters: parasite reduction
ratios 1 or 2 days after treatment began, parasite clear-
ance time, fever clearance time, median FIH/1 000
asexual parasite cpb and anaemia recovery time. P
values of <0.05 were taken to indicate significant dif-
ferences. Data were double entered serially using pa-
tients’ codes and were only analysed at the end of the
study.
Ethical clearance
The study protocol was approved by the Ministry of
Health, Ibadan, and the National Health Research Ethics
Committee, Abuja, Nigeria. The reference numbers are:
Ministry of Health Ibadan - AD 13/262/56 (7 March
2006), AD 13/479/978 (December 2015); National Health
Research Ethics Committee - NHREC/01/01/2007-28/10/
2009d (30 October 2009), NHREC/01/01/2007-28/10/2013
(29 October 2013), NHREC/01/01/2007-22/10/2014
(30 October 2014). Written informed consents were
obtained from parents/guardians of the children.
Results
Patient characteristics at enrolment
During the study period, 1 346 children of which 437
children (32%) who were anaemic at presentation were
included in the present study (Fig. 3). A total of 829 and
517 children were treated with artesunate-amodiaquine
and artemether-lumefantrine, respectively. Of the 437
anaemic children, anaemia was mild, moderate or severe
in 395 (90.4%), 40 (9.1%) or 2 (0.5%) children, respectively.
Overall, the mean age of these children was 5.3 years
(95%CI: 5.1-5.5, range 0.5-15). The clinical and parasito-
logical characteristics of these children are summarised in
Table 1. Overall (see All treatments section in Table 1),
children with anaemia were significantly younger, had sig-




Parasitological efficacy Overall, during the 7-year
period, parasitological efficacy (ACPR) on day 28 with
both treatments was 96.5% (95%CI: 91.8-100) and it in-
creased significantly with time over the study period
[94.6% (95%CI: 84.1-100) versus 98.8% (95%CI: 84.0-100)
P = 0.007 test for trend, in 2008–2010 and 2011–2014,
respectively]. Overall, parasitological efficacy on day 28
was significantly higher in children treated with
artesunate-amodiaquine compared with children treated
with artemether-lumefantrine [97% (95%CI: 92.8-100)
versus 96.4% (95%CI: 91.3-99.4); P = 0.02)]. The signifi-
cant increase in parasitological efficacy over the years
involved both artesunate-amodiaquine and artemether-
lumefantrine and both anaemic and non-anaemic children
(data not shown).
Overall, parasitological efficacy was similar in anaemic
and non-anaemic children (97.5% (95%CI: 92.4-100) ver-
sus 96.1% (95%CI: 91.2-100), P = 0.3, respectively). In
children treated with artesunate-amodiaquine, PCR-
uncorrected and corrected parasitological efficacy
were similar in anaemic and non-anaemic children at
all study sites (Table 2). Similarly, in children treated
with artemether-lumefantrine, PCR-uncorrected and
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corrected parasitological efficacy were similar in an-
aemic and non-anaemic children at all sites (Table 2).
Overall, early treatment failure (ETF) occurred in 1
child treated with artesunate-amodiaquine. Late para-
sitological failure (LPF) occurred in 71 children: 37 of
818 children treated with artesunate-amodiaquine and
34 of 505 children treated with artemether-lumefantrine.
There was no significant difference in the proportions of
children with late parasitological failure in the two treat-
ment groups (P = 0.11). There was also no significant
difference in the proportions of children with late para-
sitological failure in anaemic and non-anaemic groups:
28 of 429 anaemic children versus 43 of 894 non-
anaemic children (P = 0.24). The proportions of children
Table 2 Efficacy of artesunate-amodiaquine or artemether-lumefantrine in anaemic and non-anaemic malarious children according
to study site and year of enrolment
Site (Year) Haematocrit status PCR uncorrected PCR corrected
ACPR_u Failure_u Total ACPR_c Recrudescence Total P value
Artesunate-amodiaquine
Ibadan (2008–2010) Anaemia 84 5 89 85 3 88
No anaemia 286 14 300 286 11 297 1.0
Damboa (2009–2010) Anaemia 40 0 40 40 0 40
No anaemia 21 0 21 21 0 21 -
Agbani (2009–2010) Anaemia 26 5 31 25 5 30
No anaemia 21 2 23 20 2 22 0.44
Makarfi (2009–2010) Anaemia 22 0 22 22 0 22
No anaemia 39 0 39 39 0 39 -
Ijede (2009–2010) Anaemia 19 1 20 19 1 20
No anaemia 28 0 28 28 0 28 -
Barkin Ladi (2009–2010) Anaemia 11 4 15 11 0 11
No anaemia 36 6 42 36 4 40 -
Ibadan (2011–2014) Anaemia 34 1 35 34 0 34
No anaemia 121 3 124 119 4 123 -
Total (2008–2014) Anaemia 236 16 252 236 9 245
No anaemia 552 25 577 549 21 570 0.85
Artemether-lumefantrine
Ibadan (2008–2010) Anaemia 43 2 45 43 2 45
No anaemia 129 11 140 132 8 140 1.0
Damboa (2009–2010) Anaemia 33 3 36 33 2 35
No anaemia 18 2 20 18 1 19 1.0
Agbani (2009–2010) Anaemia 33 2 35 33 0 33
No anaemia 19 4 23 19 4 23 -
Makarfi (2009–2010) Anaemia 20 1 21 19 1 20
No anaemia 37 0 37 37 0 37 -
Ijede (2009–2010) Anaemia 19 1 20 19 0 19
No anaemia 24 2 26 26 0 26 -
Barkin Ladi (2009–2010) Anaemia 8 4 12 8 2 10
No anaemia 34 6 40 34 4 38 0.59
Ibadan (2011–2014) Anaemia 15 1 16 15 1 16
No anaemia 42 4 46 42 3 45 1.0
Total (2008–2014) Anaemia 171 14 185 170 8 178
No anaemia 303 29 332 306 20 326 0.57
PCR polymerase chain reaction, ACPR_u adequate clinical and parasitological response uncorrected, ACPR_c adequate clinical and parasitological response
corrected, Failure_u treatment failure uncorrected, AA artesunate-amodiaquine, AL artemether-lumefantrine, ALL all children
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with late parasitological failure did not increase over the
years: 63 of 1 105 in 2008–2010 versus 8 of 218 in
2011–2014 (P = 0.12 test for trend).
Recrudescent and new infections Parasitaemia was
detectable in 84 children before day 28–42. Of these, 17
were new infections, 57 were recrudescent infections of
P. falciparum and in 10 cases, PCR results were incon-
clusive. Of the recrudescent infections, 27 were in chil-
dren treated with artesunate-amodiaquine and 30 were
in children treated with artemether-lumefantrine. The
proportion of children with recrudescent infections
was significantly higher in artemether-lumefantrine-
treated group than in artesunate-amodiaquine-treated
group (P = 0.03). However, there was no significant
difference in the proportions of children with recru-
descent infections in anaemic and non-anaemic chil-
dren (16 of 437 versus 41 of 909, P = 0.56). Median
time to recrudescent infections was similar in
artesunate-amodiaquine- and artemether-lumefantrine
- treated children (28 days (range 14–42) versus
28 days (range 11–42), P = 0.9). Similarly, time to re-
crudescent infections was similar in anaemic and non-
anaemic children (28 days (range 14–42) versus 28 days
(range 11–42), P = 0.94). Overall, the probabilities of
reappearance of asexual parasitaemia after treatment
were significantly higher with artemether-lumefantrine
compared with artesunate-amodiaquine (Log-rank
statistic = 7.37, P = 0.007, Fig. 4a). The probabilities of
reappearance of asexual parasitaemia after treatment
with the two (artesunate-amodiaquine or artemether-
lumefantrine) were similar in anaemic and non-anaemic
children (Log-rank statistic = 1.04, P = 0.31, Fig. 4b).
Prevalence of asexual parasitaemia on day 1 Overall,
asexual parasite prevalence 1 day after treatment
began was 34% (461 of 1 346 children). The preva-
lence was 28% (236 of 829 children) in children
treated with artesunate-amodiaquine and 44% (225 of
517 children) in those treated with artemether-
lumefantrine. The difference between these two propor-
tions was significant (P < 0.0001). Parasite prevalence
1 day after treatment began was significantly higher
in anaemic compared to non-anaemic children (175
of 437 children [40%] versus 286 of 909 children
[31%]; P = 0.002).
Parasite positivity on day 3 Overall, parasite positivity
on day 3 was 0.7% (9 of 1 346 children and it was similar
in children treated with artesunate-amodiaquine or
artemether-lumefantrine (6 of 829 versus 3 of 517 chil-
dren, P = 1.0). Of the 286 children who had enrolment
parasitaemia ≥100 000 μL−1, 3 children (2 in artesunate-
amodiaquine and 1 in artemether-lumefantrine treatment
groups) had parasitaemia on day 3, suggesting there was
no in-vivo evidence of any cluster of cases with slow para-
site clearance after treatment. Parasite positivity on day 3
was similar in anaemic and non-anaemic children (6 of
437 versus 3 of 909; P = 0.07). All 3 children with parasite
positivity on day 3 who had parasitaemia ≥100 000 μL−1 at
enrolment were anaemic at presentation.
Parasite reduction ratio 1 day after treatment began
(PRRD1) Overall, geometric mean parasite reduction
ratio 1 day after treatment started was 3.1 × 103
(range 1.1 × 10−1–2.1 × 106). Geometric mean parasite
reduction ratio 1 day after treatment began was
significantly higher in artesunate-amodiaquine- com-
pared to artemether-lumefantrine-treated children
[5.2 × 103 (range 1.1 × 10−1–1.1 × 106) versus 1.3 × 103
(range 4.1 × 10−1–2.1 × 106); P < 0.0001] (Fig. 5a). PRRD1
was significantly higher in non-anaemic compared to
anaemic children [4.3 × 103 (range 3.2 × 10−1–1.1 × 106)
versus 1.6 × 103 (range 1.1 × 10−1–2.1 × 106); P < 0.0001].
PRRD1 increased with year following treatment and was
significantly higher in 2011–2014 than in 2008–2010
with both ACTs [1.1 × 104 (range 7.1 × 10−1–1.1 × 106)
versus 2.4 × 103 (range 1.1 × 10−1–2.1 × 106), P < 0.0001]
(Fig. 5b and c).
Parasite reduction ratio 2 days after treatment began
(PRRD2) Overall, geometric mean parasite reduction ra-
tio 2 days after treatment began was 2.5 × 104 (range
1.6 × 101–2.1 × 106). Geometric mean parasite reduction
ratio 2 days after treatment began was significantly higher
in artesunate-amodiaquine- compared to artemether-
lumefantrine-treated children [2.9 × 104 (range 1.6 × 101–
1.1 × 106) versus 2.0 × 104 (range 1.7 × 101–2.1 × 106), P =
0.001]. PRRD2 was significantly higher in non-anaemic
compared to anaemic children [2.9 × 104 (range 1.7 × 101–
1.1 × 106) versus 1.9 × 104 (range 1.6 × 101–2.1 × 106); P <
0.0001]. PRRD2 increased over the years: it was signifi-
cantly higher in 2011–2014 than in 2008–2010 with both
ACTs [4.8 × 104 (range 2.1 × 103–1.1 × 106) versus 2.2 ×
104 (range 1.6 × 101–2.1 × 106), P < 0.0001].
Secondary outcomes
Parasite and fever clearance Overall, parasite clearance
was significantly faster in artesunate-amodiaquine- com-
pared with artemether-lumefantrine-treated children
[1.3 day (95%CI: 1.3-1.4) versus 1.5 day (95%CI: 1.4-1.5),
P < 0.0001]. Similarly, fever clearance was significantly fas-
ter in artesunate-amodiaquine- compared with artemether-
lumefantrine-treated children [1.1 day (95%CI: 1.06 – 1.13)
versus 1.2 day (95%CI: 1.13 – 1.29), P = 0.002]. The sec-
ondary outcomes in these children according to drug
treatment or haematocrit status are shown in Table 3.
Fever and parasite clearance times were similar in
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anaemic and non-anaemic children treated with
artemether-lumefantrine. Fever but not parasite clear-
ance time was similar in anaemic and non-anaemic
children treated with artesunate-amodiaquine. Further
exploratory analysis of the children treated with
artesunate-amodiaquine when matched for age, gender,
same treatment, same day of presentation and same para-
sitaemia, showed that, parasite and fever clearance times
were similar in anaemic and non-anaemic children
[1.2 day versus 1.1 day; P = 0.14 (n = 90) and 1.0 day versus
1.1 day; P = 0.18 (n = 90), respectively]. Parasite clearance
time decreased significantly over the years [1.2 day
(95%CI: 1.2-1.3) in 2011–2014 versus 1.4 day (95%CI:
1.4-1.5) in 2008–2010; P < 0.0001]. However, fever
clearance did not change over the years [1.2 day
(95%CI: 1.0-1.3) in 2011–2014 versus 1.1 day (95%CI:
1.1-1.2) in 2008–2010; P = 0.63].
Gametocyte carriage Overall, 67 of 1 117 children (6%)
had patent gametocytaemia at enrolment. Gametocyte
carriage was similar in anaemic compared to non-
anaemic children (19 of 295 versus 48 of 822, P = 0.71).
Fig. 4 Kaplan-Meier survival estimates of asexual parasitaemia, (a) after treatment with AA (blue line) or AL (green line); [log-rank statistic = 7.37; P= 0.007],
and (b) in children with (green line) or without (blue line) anaemia at presentation [log-rank statistic = 1.04; P= 0.31]. AA, artesunate-amodiaquine;
AL, artemether-lumefantrine
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Fig. 5 Scatter plots of day 1 parasite reduction ratios (PRRD1) in children with uncomplicated P. falciparum malaria following treatment with
artesunate-amodiaquine (AA) or artemether-lumefantrine (AL): (a) all children treated with AA or AL during the period 2008–2014, (b) all children
treated with AA during the period 2008–2010 and 2011–2014 and (c) all children treated with AL between 2008–2010 and 2011–2014
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In Ibadan where gametocyte carriage at presentation was
evaluated for 7 years, gametocyte carriage did not de-
crease significantly over the study period (4 of 116, 15 of
255, 3 of 103, 7 of 68, 2 of 61 and 1 of 60 in 2008, 2009,
2010, 2011, 2012 and 2014, respectively, P = 0.41 test for
trend). Gametocytes were not detectable in peripheral
blood of all the children after day 14.
Fall in haematocrit/1 000 asexual parasites cleared from
peripheral blood
Data for evaluation of fall in haematocrit (FIH)/1 000
asexual parasites cleared from peripheral blood (cpb)
were available in 643 children (see Fig. 3). Overall, me-
dian FIH/1 000 asexual parasites cpb was 0.029 (range
0.0001-0.91) and it did not decrease over the years
[median 0.026 (range 0.0001-0.76; n = 443) in 2008–2010
versus 0.032 (range 0.0004–0.91, n = 200) in 2011–2014,
P = 0.39]. FIH/1 000 asexual parasites cleared from peri-
pheral blood was similar in children treated with
artesunate-amodiaquine and artemether-lumefantrine
[median 0.028 (range 0.0001–0.91, n = 441) versus 0.031
(range 0.0003–0.87, n = 202); P = 0.65]. FIH/1 000
asexual parasites cpb was significantly greater at lower
parasitaemias (<100 000 μL−1) compared to higher para-
sitaemias (≥100 000 μL−1) [median 0.046 (range 0.001–
0.91, n = 444) versus median 0.011 (range 0.0001–0.087,
n = 199), P < 0.0001], suggesting much haematocrit con-
servation at higher parasitaemias compared to lower
parasitaemias. In non-anaemic children, FIH/1 000
asexual parasites cleared from peripheral blood was
significantly greater compared to anaemic children
[median 0.032 (range 0.0001–0.91, n = 502) versus
median 0.022 (range 0.0004–0.62, n = 141), P = 0.007]
also suggesting much haematocrit conservation in
anaemic compared to non-anaemic children. Similarly,
FIH was significantly greater in patients with mild
compared to moderate anaemia at presentation [median
0.024 (range 0.004–0.62, n = 133) versus median 0.002
(range 0.0008–0.09, n = 8), P = 0.04]. Further exploratory
analysis showed that FIH/1 000 asexual parasites
cleared from peripheral blood was significantly greater
in non-anaemic children with enrolment parasitaemias
of 50 000 μL−1 -100 000 μL−1 compared to anaemic chil-
dren with enrolment parasitaemias of 50 000–100 000 μL−1
[median 0.037 (range 0.001–0.17, n = 126) versus median
0.026 (range 0.001–0.15, n = 48), P = 0.003].
Anaemia recovery time
Anaemia recovery time was evaluated in patients who
had ≥5 units fall in haematocrit from 30% and in
whom haematocrit measurement was done consist-
ently in >90% of the times of follow-up. Fifty eight of
185 anaemic children met the strict criteria for the
evaluation of anaemia recovery time (see Fig. 3). Mean
anaemia recovery time was 15.4 days (95%CI: 13.3–
17.4). Anaemia recovery time did not change over the
years (15.6 days (95%CI: 13–18.3, n = 39) in 2008 –
2010 versus 14.8 days (95%CI: 11.2–18.5, n = 19) in
2011–2014, P = 0.73). Anaemia recovery time was similar
in children aged <3 and ≥3 years (18.5 days (95%CI: 13.7–
23.4, n = 15) versus 14.3 days (95%CI: 12–16.5, n = 43);
P = 0.07). Anaemia recovery time was also similar in an-
aemic children with high enrolment parasitaemias
(≥100 000 μL−1) compared with those with low enrol-
ment parasitaemias (<100 000 μL−1) [14.6 days (95%CI:
11.2–18, n = 20) versus 15.7 days (95%CI: 13–18.5, n = 38),
P = 0.6]. There was no correlation between anaemia
recovery time and parasite clearance time (r = 0.071,
P = 0.58, n = 58) and between anaemia recovery time
and FIH/1 000 asexual parasites cleared from peripheral
blood (r = 0.004, P = 0.61, n = 58) in the same patients.
Temporal changes in haematocrit in anaemic children
following treatment with artesunate-amodiaquine or
artemether-lumefantrine
Temporal changes in haematocrit were evaluated in 123
of 185 (66%) children who were anaemic at presentation
and in whom haematocrit concentration was measured
in all (100%) or nearly all (90%) of the follow-up period.
The temporal changes in haematocrit are as follows: 1.
Haematocrit <30% before treatment, followed by an in-
crease to ≥30% after treatment and remaining so during the
entire period of follow-up (malaria-associated anaemia and
recovery from anaemia, n = 98 (79.7%)). 2. Haematocrit
Table 3 Fever and parasite clearance in malarious children following treatment with artesunate-amodiaquine or
artemether-lumefantrine
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<30% at presentation followed by a rise to ≥30% by day 7
and a fall to <30% between days 7 and 14 and then recovery
(anaemia-early recovery-early anaemia-late recovery, n = 12
(9.8%)). 3. Haematocrit <30% at presentation followed by a
rise to ≥30% on day 7 or 14 and two consecutive normal
haematocrit values followed by a decline to <30% after day
14 (anaemia-early recovery-late-appearing anaemia pattern,
n = 7 (5.7%)). 4. Haematocrit <30% at before treatment
began and during the entire follow-up period (persistent,
unresolved anaemia, n = 4, (3.2%). 5. Patients with multiple
falls below 30%, followed by multiple rises to ≥30% during
follow-up period (undulating pattern of anaemia, n = 2
(1.6%)). No patient was unclassifiable.
The characteristics of the seven children with anaemia
at presentation, who recovered from their anaemia and
who subsequently developed late fall in haematocrit to
<30% after day 14 are shown in Table 4. The late-
appearing anaemia after initial recovery from the anaemia
at presentation was characterised by an age ≤5 years (5 of
7 children), relatively high enrolment parasitaemia (6 of 7
had >50 000 asexual parasitaemia μL−1), rapid clearance of
asexual parasitaemia [6 of 7 cleared by day 1] and low
FIH/1 000 asexual parasites (cpb). Six of these 7 children
were treated with artesunate-amodiaquine. Of the
children treated with artesunate-amodiaquine, 4 were
given total doses of artesunate ≥ 10 mg/kg over three
days.
For comparison, the characteristics of 8 of 568 non-
anaemic children at presentation who subsequently de-
veloped late-appearing anaemia after day 14 are shown
in Table 5. The late-appearing anaemia was characterised
by an age >5 years (7 of 8 children), relatively high enrol-
ment parasitaemia (7 of 8 had parasitaemia >50 000 asexual
parasitaemia μL−1), rapid clearance of asexual parasitaemia
(5 of 8 cleared by day 1) and low FIH/1 000 asexual para-
sites cpb. Of these children, 6 were treated with
artesunate-amodiaquine. Of the children treated with
artesunate-amodiaquine, 5 were given total doses of
artesunate ≥10 mg/kg over three days. Apart from age,
all parameters appear to be similar in children with and
without anaemia at presentation who developed late-
appearing anaemia after day 14.
Relationship between AUC of deficit in haematocrit from
30% versus time and FIH/1 000 asexual parasites cleared
from peripheral blood
In the 7 children who were anaemic at presentation,
who recovered from their anaemia and who subse-
quently developed anaemia 21 or more days after treat-
ment began (see Table 4), the AUC of deficit in
haematocrit from 30% versus time at presentation were
similar to AUC of deficit in haematocrit from 30% versus
time when anaemia developed 21 or more days after
treatment began [33.9%.day (95%CI: 13.83–54.1) versus
19.9%.day (95%CI: 3.62–48.36); P = 0.09]. There was no
correlation between AUC of deficit in haematocrit from
30% versus time of the late-appearing anaemia and
FIH/1 000 asexual parasites cleared from peripheral
blood (r = 0.45; P = 0.31).
Kinetics of the disposition of the deficit in haematocrit
from 30%
The kinetics of the disposition of the deficit in haemato-
crit were evaluated in 58 children (n = 43 for artesunate-
amodiaquine and n = 15 for artemether-lumefantrine)
with the following demographic and other characteris-
tics: mean age 5.2 years (range 1.1-13); mean duration of
illness 3.5 days (range 1–7); mean body temperature
38.4°C (range 36.2-41); mean haematocrit 23.2% (range
17–25); geometric mean parasitaemia 61 752 asexual
form /μL (range 2 100 – 288 461); mean fever clearance
time 1.2 days (1–7); mean parasite clearance time
1.2 days (range 1–3); mean anaemia recovery time
15.4 days (range 2–28). None of the patients had late-
appearing anaemia. Overall, there was monoexponential
decline of the deficit in haematocrit from 30% with an
estimated mean elimination half-time (t½el, t½anaemia) of
1.4 days (95%CI: 1.2-1.6) (Fig. 6). In <5 (n = 34) and ≥5
(n = 24) year olds, estimated mean elimination half-times
were 1.5 days (95%CI: 1.2-1.8) and 1.3 days (95%CI: 0.9-1.6)
and they were similar (P = 0.38). The estimated mean t½el
values were also similar in artesunate-amodiaquine-
(1.4 days, 95%CI: 1.1–1.7) and artemether-lumefantrine-
treated (1.3 days, 95%CI: 0.9–1.7) children (P = 0.66)
(Fig. 6). Estimated mean half-times were also similar in
children with enrolment parasitaemia ≥100 000 μL−1
and those with <100 000 μL−1 [1.2 days (95%CI: 0.9–
1.4, n = 20) versus 1.5 days (95%CI: 1.2–1.8, n = 38); P =
0.19], and in children with mild and moderate anaemia
at presentation [1.4 days (95%CI: 1.1–1.6, n = 48) versus
1.6 days (95%CI: 1.1–2.0, n = 10); P = 0.46].
Overall, mean areas under curve of deficit in haemato-
crit from 30% versus time (AUCdef) value were 63.7%.day
(95%CI: 51.0–76.4). Mean AUCs were similar in
artesunate-amodiaquine- and artemether-lumefantrine -
treated children [59.4%.day (95%CI: 46.3–72.5) versus
76.0%.day (95%CI: 41.7–110.3), P = 0.26]. Mean AUCdef
values were also similar in <5 and ≥5 year olds [65.2%.day
(95%CI: 49.9–80.4, n = 34) and 61.6%.day (95%CI: 38.3–
84.8, n = 24), P = 0.78], and in children with enrolment
parasitaemia ≥100 000 μL−1 and those with <100 000 μL−1
[65.8%.day (95%CI: 43.8–87.8; n = 20) and 62.5%.day
(95%CI: 46.3–78.8; n = 38), P = 0.81].
Relationship between half - time of decline in
haematocrit deficit and anaemia recovery time
The relationship between the half-time of decline in
haematocrit deficit from 30% and anaemia recovery
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time in the same patients with anaemia at presentation
was evaluated in 58 children. The mean half-time of de-
cline in haematocrit deficit from 30% was 1.4 days
(95%CI: 1.2–1.6). The mean anaemia recovery time was
15.4 days (range 2–28). There was a significantly posi-
tive correlation between half-time of decline in haem-
atocrit deficit from 30% and anaemia recovery time in
the same patients (r = 0.69, P < 0.0001). Bland-Altman
plots of the anaemia recovery times and 9 or 10 multi-
ples of anaemia half-times are shown in Fig. 7. The
limit of agreement between anaemia recovery time and
9 multiples of anaemia half-time was not narrow. The
bias was significantly different from 0 (P = 0.0005).
However, at multiple of 10 half-times, the limit of
agreement between anaemia half-time and anaemia
recovery time was narrow. The bias at multiple of
10 anaemia half-times was statistically insignificant
(P = 0.07).
Adverse events
Adverse events were carefully monitored in 610 non-
anaemic and 185 anaemic children drawn from Ibadan
centre. Overall, 186 of 795 children [23%] (150 of 548
[27%] in artesunate-amodiaquine and 36 of 247 [15%] in
artemether-lumefantrine reported at least one adverse
event within the first week of starting treatment. There
was a significant difference in the proportions of chil-
dren reporting adverse events in both treatment groups
(P < 0.0001). Fever (70 of 548 [13%] versus 11 of 247
[4%], P = 0.0005), vomiting (38 of 548 (7%) versus 6 of
247 (2%), P = 0.016), headache (33 of 548 (6%) versus 4
of 247 (2%), P = 0.006), abdominal pain (46 of 548 (8%)
versus 3 of 247 (1%), P = 0.00002) and anorexia (26 of
548 (5%) versus 3 of 247 (1%), P = 0.013) were signifi-
cantly more common in artesunate-amodiaquine- com-
pared with artemether-lumefantrine-treated children.
Other reported adverse events (cough, weakness, puffy
face, itching and drowsiness) were similar in frequency
in the two treatment groups. One hundred and thirty
eight of 610 children without anaemia at presentation
[23%] and 48 of 185 children with anaemia at presenta-
tion [26%] reported at least one adverse event within the
first week of commencement of treatment. There was no
significant difference in the proportions of children
reporting adverse events in anaemic and non-anaemic
children (P = 0.4). The most commonly reported adverse
events in non-anaemic and anaemic children were fever
[65 of 610 (11%) versus 16 of 185 (9%), P = 0.62],
vomiting [35 of 610 (6%) versus 9 of 185 (5%), P = 0.21],
abdominal pain [31 of 610 (5%) versus 18 of 185
(10%), P = 0.03] and cough [40 of 610 (7%) versus 19




















Fig. 6 Semilog plots of deficit in haematocrit from 30% versus time in all children treated with artesunate-amodiaquine or artemether-lumefantrine
(black line) and in children treated with artesunate-amodiaquine (green line) or artemether-lumefantrine (blue line)
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Discussion
In this study, conducted during a seven year-period of
adoption of ACTs as first-line treatments of uncomplicated
P. falciparum malaria in Nigeria, artesunate-amodiaquine
proved a superior alternative to artemether-lumefantrine
as evidenced by a significantly higher PCR-corrected
28 days parasitological efficacy or better measures of
therapeutic responses. These findings were not unex-
pected as a previous relatively large study conducted in
southwest Nigeria during the first 5 years of adoption
showed similar results [36]. The PCR-corrected 28 days
efficacy of over 96% with both treatments supports con-
tinuing efficacy of ACTs in P. falciparum infections in vir-
tually all endemic areas of Nigeria since adoption as first-
line treatments in 2005. It is, however, in contradistinction
to the reports of declining responsiveness of P. falciparum
to ACTs in Kenya or Suriname [53, 54] or resistance to ar-
temisinin in the Greater Mekong subregion [5, 7].
It is intriguing that PRRD1, a less frequently evaluated
measure of therapeutic efficacy in the area of study,
was also significantly higher in children treated with
artesunate-amodiaquine compared with artemether-
lumefantrine. With respect to parasite prevalence 1 day
after treatment began being significantly lower in chil-
dren treated with artesunate-amodiaquine compared to
those treated with artemether-lumefantrine, similar dif-
ference in parasite prevalence after treatment began has
been reported between the two ACTs [55].
Overall, despite being significantly younger, parasito-
logical responses in anaemic children were similar to
those of non-anaemic children suggesting that in this
area of full sensitivity in P. falciparum to the two
ACTs, anaemia did not compromise, to any signifi-
cant extent, the therapeutic responses to both treat-
ments. The younger age of the anaemic children may be
partly responsible for the slower parasite clearance and
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Fig. 7 Bland-Altman plots of anaemia recovery times and multiples [9 (a) and 10 (b)] of anaemia half-times. Biases were 3.0, and 1.6 for plots A
and B; P = 0.0005 and 0.07; respectively. The mean values ± 1.96 standard deviation (SD) of the differences are shown. AnRT; Anaemia recovery
time, t½; half-time
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the lower parasite reduction ratios 1 and 2 days after treat-
ment began in artesunate-amodiaquine-treated children
because younger children may be considered to have rela-
tively lower antimalarial immunity [56] and therefore
slower response.
The present study showed that ACTs conserved haem-
atocrit significantly at high parasitaemias compared to low
parasitaemias, in anaemic compared to non-anaemic chil-
dren, and in children with moderate compared to mild an-
aemia. The reasons for haematocrit conservation are
unclear. It is possible the mechanisms and the kinetics of
the production and disposition of the once-infected red
blood cells may differ in anaemic and non-anaemic chil-
dren in the first few or more days after start of
artemisinin-based combination treatments. In this con-
text, studies are needed on the production and disposition
kinetics of infected and once-infected red blood cells in
anaemic and non-anaemic children in this endemic area
following artemisinin-based combination treatments.
Successful treatment of P. falciparum malaria with ACTs
is often followed by increases in haematocrit or haemoglo-
bin. This often led to recovery from uncomplicated
malaria-associated anaemia [13, 17, 35, 40, 57]. In this rela-
tively large series of anaemic children, anaemia recovery
time in children with ≥5 units deficit in haematocrit from
30% was approximately 2 weeks. This recovery time is simi-
lar to that recently reported in very young children [58].
The monoexponential declines of the deficits in haem-
atocrit from 30% would suggest that, using a non-
compartment model, recovery from uncomplicated
malaria-associated anaemia is a first-order process [47].
The anaemia recovery time : anaemia half-time of 10, and
the insignificant bias between anaemia recovery time and
10 multiples of anaemia half-time by Bland-Altman ana-
lysis suggest that anaemia recovery time and 10 multiples
of anaemia half-time can be used interchangeably in the
evaluation of recovery from uncomplicated P. falciparum
malaria-associated anaemia. This finding was expected
because in a simple one-compartment pharmacokinetic
model approximately 99.9% of an elimination process
would have been completed in 10 half-times [48]. Thus,
there is a pharmacokinetic equivalent (anaemia half-time)
of a pharmacodynamic process (anaemia recovery time) in
the same patients.
In children who were anaemic at presentation, the com-
monest temporal change in haematocrit following treat-
ment was recovery from the associated anaemia. However,
a relatively asymptomatic late-appearing anaemia oc-
curred in 6% of anaemic children, who initially recovered
from their malaria-associated anaemia following treat-
ment. It would also appear late-appearing anaemia was
significantly more frequent in anaemic compared to non-
anaemic children. The relative absence of symptoms when
late-appearing anaemia occurred, may make it difficult to
diagnose late-appearing anaemia in children with uncom-
plicated infections following artemisinin-based combin-
ation treatments. The absence of overt symptoms and
signs of acute haemolysis and uneventful recovery from
the late-appearing anaemia would suggest that late-
appearing anaemia is a previously unrecognised feature of
artemisinin-based combination treatments in African chil-
dren with uncomplicated infections. Studies are now
under way in this endemic area of Nigeria to evaluate the
risk factors associated with the relatively asymptomatic
late-appearing anaemia after artemisinin-based combin-
ation treatments of uncomplicated P. falciparum malaria
in children.
In general, the reported adverse events within the first
week of starting treatment were indistinguishable from
the symptoms of malaria. The significantly higher fre-
quency of reported adverse events in those treated with
artesunate-amodiaquine compared with artemether-
lumefantrine are in keeping with previous report [59].
Pruritus has been reported in Nigeria children treated
with artemether-lumefantrine [60] but in this rela-
tively large series no child reported pruritus following
artemether-lumefantrine treatment.
There are limitations of the present studies. First,
although the clinical and parasitological features of chil-
dren with fall in haematocrit below 30% at presentation
were characterised, the nature of the anaemia was not
fully characterized (that is, whether it was haemolytic or
not in nature). Second, in the children with late fall in
haematocrit below 30%, quantification of once-infected
and infected red blood cells and the disposition of these
red blood cells during the course of follow-up were not
done. Third, in children with anaemia before or following
treatment with ACTs, the contribution of background
causes of anaemia in the area of study namely nutritional,
helminthic infections, or glucose-6-phosphate dehydro-
genase deficiency was not evaluated.
Conclusion
In conclusion, artesunate-amodiaquine and artemether-
lumefantrine remain efficacious treatments of uncompli-
cated P. falciparum infections in non-anaemic and an-
aemic Nigerian children in the last 7 years of adoption as
first-line treatments. These ACTs may also conserve haem-
atocrit at high parasitaemias and in anaemic children.
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